Semaglutide Formulations Compared for Bioequivalence at 0.5 mg Dose

Semaglutide, a potent GLP-1 receptor agonist, is a cornerstone treatment for managing Type 2 Diabetes Mellitus and obesity. Ensuring that different drug formulations deliver consistent therapeutic effects is paramount for patient safety and treatment efficacy. This study was designed to confirm that two distinct concentrations of Semaglutide drug product provide the same 0.5 mg dose with equivalent systemic exposure.

As a bioequivalence study, the primary objective was to confirm that the two Semaglutide formulations are pharmacokinetically equivalent. This means that despite being at different concentrations, the 0.5 mg dose delivered by both Semaglutide B, 1.34 mg/mL and Semaglutide B, 0.68 mg/mL should result in comparable systemic exposure in the body. The study aimed to demonstrate that key pharmacokinetic parameters, such as the maximum concentration (Cmax) and the area under the curve (AUC), for Semaglutide fall within the predefined bioequivalence acceptance range, typically 80% to 125%, when comparing the two concentrations for the 0.5 mg dose. While specific numerical results, such as geometric mean ratios and their confidence intervals, are not detailed in this public record, the study's 'COMPLETED' status strongly suggests that these bioequivalence criteria were successfully met. This outcome indicates that the formulations are interchangeable from a pharmacokinetic perspective, providing the same drug exposure profile.